KLRA · Insider Trading
Kailera Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by KLRA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-09 | Nur Nicholson | Chief Technology Officer | A | +220,000 deriv. | — |
| 2026-07-08 | Kathleen Tregoning | See Remarks | A | +175,000 deriv. | — |
| 2026-06-11 | Ronald C Renaud JR | CEO & President | M | +38,094 | +$199.99K |
| 2026-04-22 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | 10%+ Owner | C | +11,511,852 | — |
| 2026-04-22 | Roderick Wong | 10%+ Owner | MIXED | +21,553,640 | +$16.00M |
| 2026-04-20 | Christopher Hite | Director | A | +38,300 deriv. | — |
| 2026-04-20 | Martin Mackay | Director | A | +38,300 deriv. | — |
| 2026-04-20 | John F Milligan | Director | A | +38,300 deriv. | — |
| 2026-04-20 | Scott M. Wasserman | Chief Medical Officer | A | +200,000 deriv. | — |
| 2026-04-20 | Ronald C Renaud JR | CEO & President | A | +600,000 deriv. | — |
| 2026-04-20 | Andrew T. Kaplan | Director | MIXED | +26,255,581 | +$134.38M |
| 2026-04-20 | Paul D. Burgess | See Remarks | A | +200,000 deriv. | — |
| 2026-04-20 | Douglas W. Pagan | Chief Financial Officer | A | +200,000 deriv. | — |
| 2026-04-20 | Jamie Beth Coleman | Chief Commercial Officer | A | +150,000 deriv. | — |
| 2026-04-20 | Paula Cloghessy | Chief People Officer | A | +120,000 deriv. | — |
| 2026-04-20 | Scott Akamine | Chief Legal Officer | A | +120,000 deriv. | — |
| 2026-04-20 | Adam Koppel | Director | MIXED | +22,583,268 | +$25.00M |
| 2026-04-20 | Bain Capital Life Sciences Fund IV, L.P. | 10%+ Owner | MIXED | +112,916,340 | +$125.00M |
| 2026-04-20 | BAIN CAPITAL INVESTORS LLC | 10%+ Owner | MIXED | +131,277,905 | +$671.88M |
| 2026-04-20 | Frank Clyburn | Director | A | +38,300 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Andrew T. Kaplan | Director | 26,255,581 | $335.28M |
| Adam Koppel | Director | 22,583,268 | $288.39M |
| Bain Capital Life Sciences Fund IV, L.P. | 10%+ Owner | 22,583,268 | $288.39M |
| BAIN CAPITAL INVESTORS LLC | 10%+ Owner | 17,857,143 | $228.04M |
| Roderick Wong | 10%+ Owner | 10,776,820 | $137.62M |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. | 10%+ Owner | 9,477,720 | $121.03M |
| Ronald C Renaud JR | CEO & President | 38,094 | $486.46K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the KLRA quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.